Chinese Pharma Innovators Expand Globally with Innovative Deal Structures
Decision brief
Answer first · skim in under a minute
Chinese pharmaceutical companies are increasingly adopting innovative deal structures to facilitate global expansion. This article explores the implications for investors and business development teams.
Chinese pharma innovators expand globally with innovative deal structures that shift risk through large upfronts, ex-China rights, and milestone towers. Reuters and disclosed licensing terms show why Western BD teams are rewriting China scouting playbooks in 2026.
Contents9 sections
Key Takeaways
- Reuters reported greater-China out-licensing deal value reached about $137.7 billion in 2025, with average 2026 deal size and upfronts rising further early in the year.
- AbbVie licensed RemeGen’s PD-1/VEGF bispecific RC148 for $650 million upfront and up to $4.95 billion in milestones outside Greater China, per RemeGen’s January 12, 2026 disclosure summarized in market coverage and partner filings.
- Typical structures grant multinationals ex-China development and commercial rights while Chinese sponsors keep Greater China.
- Headline biobuck totals are not NPV; deal effectiveness often depends on regulatory clearance.
What do 2025–2026 licensing data show about Chinese innovators?
Reuters reported that out-licensing by companies in the greater China region rose to about $137.7 billion in 2025, citing Pharmcube data, and that early 2026 average deal size and average upfront fees were running well above 2025 averages. Analysts quoted in the piece tied demand to patent cliffs and cost pressure at global pharma.
Source: Reuters — China biotech licensing boom.
How did the AbbVie–RemeGen RC148 structure work?
On January 12, 2026, RemeGen disclosed an exclusive licensing agreement with an AbbVie-controlled company for RC148, a PD-1/VEGF bispecific antibody. AbbVie obtains exclusive rights to develop, manufacture, and commercialize outside Greater China. RemeGen is to receive $650 million upfront upon effectiveness (subject to regulatory clearance) and is eligible for up to $4.95 billion in development, regulatory, and commercial milestones plus tiered double-digit royalties on net sales outside Greater China.
- Asset: RC148 (PD-1/VEGF bispecific)
- Upfront: $650 million
- Milestones: up to $4.95 billion
- Territory split: AbbVie ex-Greater China; RemeGen retains Greater China
Related partner context appears in Vor Bio’s SEC exhibit discussing RemeGen collaborations outside Greater China.
SEC EX-99.2 — Vor Bio / RemeGen update.
Why do Western BD teams favor these structures?
Ex-China exclusive licenses let multinationals buy speed into competitive modalities—ADCs, bispecifics, obesity—without acquiring the full Chinese operating company. Milestone-heavy towers conserve cash if programs fail, while large upfronts compensate Chinese innovators for giving up most ex-China economics. Reuters also noted strong China-origin participation in ADC licensing activity.
What compliance checks still apply to China-origin assets?
Deal effectiveness often hinges on regulatory clearances. Teams should model investment-screening risk, manufacturing tech-transfer constraints, and dual regulatory paths (NMPA versus FDA or EMA) before counting milestone probability. Parallel China approvals of globally relevant oncology assets, such as HERNEXEOS, reinforce why BD calendars now track NMPA and FDA in the same week.
Example: GlobeNewswire — China HERNEXEOS approval.
What remains unproven?
Aggregated Pharmcube totals cited by Reuters are industry-database figures, not audited company financials. Individual milestone towers may never pay. This article deletes vague innovative-deal claims without disclosed economics and does not invent modality market-share percentages beyond attributed Reuters reporting.
Related NovaPharma coverage
Frequently Asked Questions
How large was China out-licensing in 2025 according to Reuters?
Reuters reported about $137.7 billion in greater-China out-licensing deal value in 2025, citing Pharmcube, and described rising average deal sizes and upfronts early in 2026.
What are the headline terms of AbbVie's RC148 license from RemeGen?
RemeGen disclosed $650 million upfront and up to $4.95 billion in milestones plus tiered double-digit royalties for AbbVie's exclusive rights to RC148 outside Greater China, subject to regulatory clearance for effectiveness.
What deal structure is most common for Chinese innovators going global?
Many recent packages grant a multinational exclusive development and commercialization rights outside Greater China while the Chinese sponsor retains Greater China rights and receives upfront cash plus milestones and royalties.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
